Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey
نویسندگان
چکیده
BACKGROUND Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC. PATIENTS AND METHODS Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed. RESULTS Median time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71% of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; P<0.05). CONCLUSIONS RCC patients with bone metastasis are at continuous risk of SREs, and in this survey ZOL effectively reduced this risk.
منابع مشابه
Additive clinical value of bone scintigraphy in patients with malignant tumors with absence of localized bone pain: A report on most common sex-related cancers
Introduction: Almost all malignant tumors have the potential to eventually produce bone metastasis. The aim of the current study was to report the distribution pattern and imaging characteristics of bone metastases detected by conventional whole body bone scintigraphy in patients with different types of malignancies and to assess their relationship with the complain...
متن کاملParaneoplastic hypocalcemia in a patient whit gastric cancer accompanied by osteoblastic metastasis
Paraneoplastic syndromes are generally defined as clinical disorder associated with malignant diseases, and hypocalcemia as paraneoplastic manifestation associated with cancer is a rare condition. In patient with bone metastatic cancer, osteolytic lesions are more common than osteoblastic ones which give rise to hypercalcemia and hypocalcemia is a rare condition in this group of patients. We de...
متن کاملsCD30 and sCD40L Detection in Patients with Osteosarcoma, Chondrosarcoma and Ewing Sarcoma
Background: Primary malignant bone tumors are heterogeneous groups of neoplasms, which affect mainly children and adolescents. The most common types are Osteosarcoma, Ewing sarcoma and chondrosarcoma. Elevation of sCD30 and sCD40L has been observed in lymphoma, leukemia and autoimmune disorders. Objective: To evaluate serum concentrations of sCD30 and sCD40L in patients with primary malignant b...
متن کاملMetastatic Renal cell Carcinoma Presenting as a clear-cell Tumor in Tongue: A Case Report
Introduction: Metastatic lesions of the oral cavity are extremely rare, accounting for approximately 1% of all malignant oral tumors. The most common primary sources of metastatic tumors in the oral region are, from the most to the least common, the breast, lung, kidney, bone, and colon. Renal cell carcinoma accounts for nearly 3% of all adult malignancies. It usually metastasizes to the lungs,...
متن کاملCalculation of the Dose of Samarium-153-Ethylene Diamine Tetramethylene Phosphonate (153Sm-EDTMP) as a Radiopharmaceutical for Pain Relief of bone Metastasis
Introduction One of the important applications of nuclear physics in medicine is the use of radioactive elements as radiopharmaceuticals. Metastatic bone disease is the most common form of malignant bone tumors. Samarium-153-ethylene diamine tetramethylene phosphonate (153Sm-EDTMP) as a radiopharmaceutical is used for pain palliation. This radiopharmaceutical usually emits beta particles, which...
متن کامل